Association of human leukocyte antigen-DR-DQ-DP haplotypes with the risk of hepatitis B virus-related hepatocellular carcinoma

Abstract

Aim: Genetic polymorphisms of human leukocyte antigen (HLA) class II molecules are associated with chronic hepatitis B virus (HBV) infection. We aimed to investigate the impacts of HLA-II haplotypes on viral evolution and the risks of HBV-caused liver diseases.

Methods: HLA-DR-DQ-DP haplotypes were estimated in 1210 healthy controls, 296 HBV clearance subjects, 301 asymptomatic hepatitis B surface antigen carriers, 770 chronic hepatitis B patients, 443 HBV-related liver cirrhosis (LC) patients, and 1037 HBV-related hepatocellular carcinoma (HCC) patients. HBV mutations were determined by sequencing. The associations of HLA-DR-DQ-DP haplotypes with viral mutations and the risks of liver diseases were assessed by multivariate logistic regression.

Results: Compared to HBV-free subjects, the haplotypes CCAACG, CCGACG, TCAATA, and TCGATA were associated with decreased HCC risk, with an odds ratio (OR) [95% confidence interval (CI)] of 0.62 (0.40-0.95), 0.60 (0.39-0.92), 0.73 (0.54-0.98), and 0.58 (0.42-0.78), respectively. CCAACG, CCGACG, and TCAATA were significantly associated with decreased frequencies of the HCC-risk HBV mutations: preS1 deletion, APOBEC-signature HBV mutations in the core promoter and preS regions, A51C/T, G104C/T, and G146C/T. TCGATA and TTAACG were associated with increased LC risk, with an OR (95%CI) of 1.54 (1.03-2.30) and 2.23 (1.50-3.33), respectively. However, TCGATA and TTAACG were not consistently associated with the cirrhosis-risk HBV mutations.

Conclusion: CCAACG, CCGACG, and TCAATA are inversely associated with HCC risk, possibly because they are involved in creating an immune microenvironment attenuating the generation of HCC-risk HBV mutations. TCGATA and TTAACG might predispose the polarity of immunity towards Th17 isotype related to LC.

Keywords

Chronic hepatitis B / HBV mutation / hepatocellular carcinoma / human leukocyte antigen class II / haplotype

References

[1] Sung H,Siegel RL.Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] Jiang D,Liu W.Trends in cancer mortality in China from 2004 to 2018: a nationwide longitudinal study.Cancer Commun (Lond)2021;41:1024-36 PMCID:PMC8504142

[3] Yang F,Yang Y.Contribution of hepatitis B virus infection to the aggressiveness of primary liver cancer: a clinical epidemiological study in Eastern China.Front Oncol2019;9:370 PMCID:PMC6537574

[4] Wang XY,Lu XM.Changing risk factors for hepatocellular carcinoma in hyperendemic regions in the era of universal hepatitis B vaccination.Cancer Epidemiol2020;67:101775

[5] Yin J,He Y.Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China: a community-based study.Cancer Epidemiol Biomarkers Prev2010;19:777-86

[6] Huang YT,Yang HI.Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C.J Clin Oncol2011;29:3643-50 PMCID:PMC4874144

[7] Yin J,Liu S.Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma.Am J Gastroenterol2011;106:81-92

[8] Yin J,Zhang H.Significant association of different preS mutations with hepatitis B-related cirrhosis or hepatocellular carcinoma.J Gastroenterol2010;45:1063-71

[9] Lim SG,Guindon S.Viral quasi-species evolution during hepatitis Be antigen seroconversion.Gastroenterology2007;133:951-8

[10] Liu W,Yang F.Genetic Polymorphisms predisposing the interleukin 6-induced APOBEC3B-UNG imbalance increase HCC risk via promoting the generation of APOBEC-signature HBV mutations.Clin Cancer Res2019;25:5525-36

[11] Yin J,Li N.Compartmentalized evolution of hepatitis B virus contributes differently to the prognosis of hepatocellular carcinoma.Carcinogenesis2021;42:461-70

[12] Liang YJ,Chen CL.Clinical implications of HBV PreS/S mutations and the effects of PreS2 deletion on mitochondria, liver fibrosis, and cancer development.Hepatology2021;74:641-55

[13] Anugwom CM,Akbar SMF.Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology.Hepatoma Res2021;7:23 PMCID:PMC8057710

[14] Tai DI.The role of genetic factors in HBV-related HCC: perspectives from local genetic backgrounds and clinical epidemiology.Hepatoma Res2020;6:74

[15] Lin CL.Prevention of hepatitis B virus-related hepatocellular carcinoma.Hepatoma Res2021;7:9

[16] Kamatani Y,Ochi H.A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians.Nat Genet2009;41:591-5

[17] Hu Z,Zhai X.New loci associated with chronic hepatitis B virus infection in Han Chinese.Nat Genet2013;45:1499-503

[18] Tan W,Dan Y.Genome-wide association study identifies HLA-DR variants conferring risk of HBV-related acute-on-chronic liver failure.Gut2018;67:757-66

[19] Deng Y,Liu W.The genetic polymorphism down-regulating HLA-DRB1 enhancer activity facilitates HBV persistence, evolution and hepatocarcinogenesis in the Chinese Han population.J Viral Hepat2020;27:1150-61

[20] Ji X,Li B.Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.Infect Genet Evol2014;28:201-9

[21] Zhang Q,Zhang Y.HLA-DP polymorphisms affect the outcomes of chronic hepatitis B virus infections, possibly through interacting with viral mutations.J Virol2013;87:12176-86 PMCID:PMC3807892

[22] Nishida N,Sawai H.Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine.Hepatology2018;68:848-58 PMCID:PMC6175380

[23] Jiang DK,Cao G.Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma.Nat Genet2013;45:72-5 PMCID:PMC4105840

[24] Jiang DK,Yu H.Genetic variants in five novel loci including CFB and CD40 predispose to chronic hepatitis B.Hepatology2015;62:118-28

[25] Kim LH,Namgoong S.Replication of genome wide association studies on hepatocellular carcinoma susceptibility loci of STAT4 and HLA-DQ in a Korean population.Infect Genet Evol2015;33:72-6

[26] Mbarek H,Urabe Y.A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population.Hum Mol Genet2011;20:3884-92

[27] Schaid DJ,Tines DE,Poland GA.Score tests for association between traits and haplotypes when linkage phase is ambiguous.Am J Hum Genet2002;70:425-34 PMCID:PMC384917

[28] Zhang HW,Li YT.Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China.Gut2008;57:1713-20 PMCID:PMC2582333

[29] Gu Y,Lian Y.Serum HBV pregenomic RNA is correlated with Th1/Th2 immunity in treatment-naïve chronic hepatitis B patients.J Med Virol2020;92:317-28 PMCID:PMC7004183

[30] Mo R,Lai R.Persistently elevated circulating Th22 reversely correlates with prognosis in HBV-related acute-on-chronic liver failure.J Gastroenterol Hepatol2017;32:677-86

[31] Li X,Hua X.Levels of hepatic Th17 cells and regulatory T cells upregulated by hepatic stellate cells in advanced HBV-related liver fibrosis.J Transl Med2017;15:75 PMCID:PMC5387242

[32] O'Brien TR,Pfeiffer RM.Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver.Genes Immun2011;12:428-33 PMCID:PMC3169805

[33] Li K,Guo T.Th17/Treg imbalance is an indicator of liver cirrhosis process and a risk factor for HCC occurrence in HBV patients.Clin Res Hepatol Gastroenterol2017;41:399-407

[34] Li N,Fuji H.Interleukin-17 in liver disease pathogenesis.Semin Liver Dis2021;41:507-15

[35] Zhang Q,Liu S,Jin Z.Interleukin-35 suppresses interleukin-9-secreting CD4⁺ T cell activity in patients with hepatitis B-related hepatocellular carcinoma.Front Immunol2021;12:645835 PMCID:PMC8222719